mAbXell
mAbXell is dedicated to providing reliable and reproducible recombinant antibodies in various forms for diversified applications. Their team of scientists has made over 1000 recombinant antibodies in the past decade, offering services such as de novo discovery of monoclonal antibodies, antibody humanization, affinity maturation, and more. They focus on flexibility, diversity, and efficiency to meet project goals and deadlines.
Industries
Nr. of Employees
small (1-50)
mAbXell
mAbXell, Inc., 3698 Haven Ave. Suite A, Redwood City, CA 94063
Products
Recombinant Antibodies
Development of recombinant antibodies for various applications, ensuring reproducibility and reliability.
De Novo Discovery of Monoclonal Antibodies
Discovery of new monoclonal antibodies tailored to specific needs.
Antibody Humanization
Modification of antibodies to make them more human-like, reducing immunogenicity.
Antibody Affinity Maturation
Enhancement of antibody binding strength through molecular evolution techniques.
Construction of Recombinant Antibody Library
Creation of scFv libraries from customer cells or synthetic sources for unique antibody generation.
Generating Antigen Specific Antibodies
Development of antibodies specific to antigens using custom strategies and in-house libraries.
Recombinant Antibodies
Development of recombinant antibodies for various applications, ensuring reproducibility and reliability.
De Novo Discovery of Monoclonal Antibodies
Discovery of new monoclonal antibodies tailored to specific needs.
Antibody Humanization
Modification of antibodies to make them more human-like, reducing immunogenicity.
Antibody Affinity Maturation
Enhancement of antibody binding strength through molecular evolution techniques.
Construction of Recombinant Antibody Library
Creation of scFv libraries from customer cells or synthetic sources for unique antibody generation.
Generating Antigen Specific Antibodies
Development of antibodies specific to antigens using custom strategies and in-house libraries.
Services
Creation of high-quality scFv libraries from customer-provided cells or synthetic/semi-synthetic sources to support discovery of unique binders without attached IP.
Custom discovery strategies per antigen, screening of in-house scFv libraries, and delivery of unique antigen-specific antibodies in formats such as IgG or scFv.
Molecular evolution and engineering services to improve antibody properties including affinity maturation, humanization, epitope targeting, reduced immunogenicity, species specificity, and thermostability.
Small-scale production of antibodies in requested formats (IgG with Fc from different species, scFv, scFv dimer, scFv fusion, Fab), provided via transient expression or development of stable expression cell lines.
Design and delivery of custom expression constructs and plasmids to support antibody expression, reformatting, and functional studies.
Creation of high-quality scFv libraries from customer-provided cells or synthetic/semi-synthetic sources to support discovery of unique binders without attached IP.
Custom discovery strategies per antigen, screening of in-house scFv libraries, and delivery of unique antigen-specific antibodies in formats such as IgG or scFv.
Molecular evolution and engineering services to improve antibody properties including affinity maturation, humanization, epitope targeting, reduced immunogenicity, species specificity, and thermostability.
Small-scale production of antibodies in requested formats (IgG with Fc from different species, scFv, scFv dimer, scFv fusion, Fab), provided via transient expression or development of stable expression cell lines.
Design and delivery of custom expression constructs and plasmids to support antibody expression, reformatting, and functional studies.
Expertise Areas
- Recombinant antibody discovery
- Antibody engineering and optimization
- Display-based screening (phage and yeast)
- Antibody library construction and management
Key Technologies
- Phage display
- Yeast display
- scFv libraries
- Directed evolution
News & Updates
Research on internalizing antibodies to basal breast cancer cells.
Study on neutralizing KIT oncogenic signaling in leukemia.
Development of a human scFv phage display library for antibody reformatting.
Research on anti-CD83 monoclonal antibody for dendritic cell depletion.
Method for high throughput identification of monoclonal antibodies.
Research on blood-brain barrier selective antibody fragments.
Research on internalizing antibodies to basal breast cancer cells.
Study on neutralizing KIT oncogenic signaling in leukemia.
Development of a human scFv phage display library for antibody reformatting.
Research on anti-CD83 monoclonal antibody for dendritic cell depletion.
Method for high throughput identification of monoclonal antibodies.
Research on blood-brain barrier selective antibody fragments.